Supplementary Table S4: Antitumor activity in patients receiving treatment for >16 weeks

Tumor type	Best response	Dose, mg	Time on study treatment, days	Number of prior regimens	Most recent prior regimen	Time on last prior regimen, days
NSCLC*	SD	30 21/7	224	4	Gemcitabine/Alvocidib	37
Basal cell†	SD	60 21/7	392	2	Docetaxel	64
NSCLC*	SD	60 21/7	216	5	Pemetrexed	99
NHL† ‡	SD	120 21/7	330	11	Rituximab	207
NSCLC*§	PR	225 21/7	616	4	Pemetrexed	43
Prostate **	SD	600 21/7	198	1	Biclutamide/Leuprorelin	764
NSCLC†	SD	600 21/7	132	4	Gemcitabine	72
Breast† (*HER2* amplified)	SD	600 21/7	160	10	Vinorelbine/Bevacizumab	127
Pancreas†	SD	100 CDD	177	6	Gemcitabine/Capecitabine/ Erlotinib	117
Adenoid cystic†	SD	100 CDD	721	1	Investigational	100
Colon*	SD	400 CDD	200	6	Investigational	55
NSCLC†	SD	600 CDD	168	4	Pemetrexed	366
Tongue (*PIK3CA E545K*)	SD	600 CDD	230	4	Cisplatin/Docetaxel/5FU	7
NSCLC	SD	600 CDD	175	4	Docetaxel	71

*No mutations affecting PI3K pathway detected; †tumor mutational analysis not performed; ‡enrollment of this patient occurred after a special allowance was granted by the sponsor; §Dose escalation to 400mg after 40 weeks; **PSA normalization >5 months. 21/7 = dose administered for the first 21 days of a 28-day cycle; CDD = continuous once-daily dosing; NA = not applicable; NHL = non-Hodgkin lymphoma; NSCLC = non-small cell lung cancer; PR = partial response; SD = stable disease.